Vanguard Group’s Altimmune ALT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
$34.3M Buy
9,491,159
+3,117,521
+49% +$13.6M ﹤0.01% 2369
2025
Q3
$24M Buy
6,373,638
+1,206,514
+23% +$4.66M ﹤0.01% 2537
2025
Q2
$20M Buy
5,167,124
+759,662
+17% +$4.11M ﹤0.01% 2559
2025
Q1
$22M Sell
4,407,462
-24,150
-0.5% -$153K ﹤0.01% 2465
2024
Q4
$32M Sell
4,431,612
-552,246
-11% -$4.22M ﹤0.01% 2355
2024
Q3
$30.6M Buy
4,983,858
+77,244
+2% +$523K ﹤0.01% 2395
2024
Q2
$32.6M Buy
4,906,614
+1,777,886
+57% +$13.1M ﹤0.01% 2325
2024
Q1
$31.9M Sell
3,128,728
-443,244
-12% -$4.51M ﹤0.01% 2368
2023
Q4
$40.2M Buy
3,571,972
+227,677
+7% +$951K ﹤0.01% 2278
2023
Q3
$8.7M Buy
3,344,295
+38,323
+1% +$110K ﹤0.01% 2957
2023
Q2
$11.7M Buy
3,305,972
+768,251
+30% +$3.45M ﹤0.01% 2853
2023
Q1
$10.7M Buy
2,537,721
+5,301
+0.2% +$63K ﹤0.01% 2901
2022
Q4
$41.7M Buy
2,532,420
+505,378
+25% +$5.68M ﹤0.01% 2271
2022
Q3
$25.9M Buy
2,027,042
+301,496
+17% +$4.45M ﹤0.01% 2522
2022
Q2
$20.2M Sell
1,725,546
-91,369
-5% -$563K ﹤0.01% 2637
2022
Q1
$11.1M Buy
1,816,915
+83,160
+5% +$612K ﹤0.01% 3096
2021
Q4
$15.9M Buy
1,733,755
+97,398
+6% +$1.03M ﹤0.01% 2959
2021
Q3
$18.5M Buy
1,636,357
+50,264
+3% +$611K ﹤0.01% 2906
2021
Q2
$15.6M Buy
1,586,093
+258,883
+20% +$3.54M ﹤0.01% 2966
2021
Q1
$18.8M Buy
1,327,210
+89,984
+7% +$1.45M ﹤0.01% 2816
2020
Q4
$14M Buy
1,237,226
+33,923
+3% +$400K ﹤0.01% 2820
2020
Q3
$15.9M Buy
1,203,303
+597,258
+99% +$11.9M ﹤0.01% 2569
2020
Q2
$6.49M Buy
606,045
+25,336
+4% +$139K ﹤0.01% 2978
2020
Q1
$1.86M Buy
580,709
+46,534
+9% +$107K ﹤0.01% 3329
2019
Q4
$1.01M Hold
534,175
﹤0.01% 3638
2019
Q3
$1.04M Buy
534,175
+54,540
+11% +$121K ﹤0.01% 3641
2019
Q2
$1.14M Buy
479,635
+109,977
+30% +$294K ﹤0.01% 3636
2019
Q1
$1.07M Buy
369,658
+259,289
+235% +$773K ﹤0.01% 3610
2018
Q4
$227K Buy
+110,369
New +$391K ﹤0.01% 3881
2018
Q3
Sell
-9,212
Closed -$123K 4169
2018
Q2
$123K Buy
9,212
+18
+0.2% +$354 ﹤0.01% 4035
2018
Q1
$320K Buy
9,194
+74
+0.8% +$3.71K ﹤0.01% 3883
2017
Q4
$544K Buy
9,120
+55
+0.6% +$3.51K ﹤0.01% 3726
2017
Q3
$631K Buy
9,065
+123
+1% +$9.16K ﹤0.01% 3696
2017
Q2
$858K Sell
8,942
-3,963
-31% -$659K ﹤0.01% 3605
2017
Q1
$3.14M Buy
12,905
+6,286
+95% +$3.36M ﹤0.01% 3232
2016
Q4
$6.45M Buy
6,619
+123
+2% +$110K ﹤0.01% 2947
2016
Q3
$5.65M Sell
6,496
-31
-0.5% -$24.3K ﹤0.01% 2945
2016
Q2
$4.78M Buy
6,527
+671
+11% +$459K ﹤0.01% 3007
2016
Q1
$3.32M Buy
5,856
+140
+2% +$71.6K ﹤0.01% 3168
2015
Q4
$3.26M Buy
5,716
+384
+7% +$191K ﹤0.01% 3195
2015
Q3
$2.13M Buy
5,332
+14
+0.3% +$6.63K ﹤0.01% 3351
2015
Q2
$2.87M Sell
5,318
-29
-0.5% -$14.7K ﹤0.01% 3263
2015
Q1
$2.62M Buy
5,347
+43
+0.8% +$21.4K ﹤0.01% 3294
2014
Q4
$2.88M Buy
5,304
+668
+14% +$343K ﹤0.01% 3145
2014
Q3
$2.48M Buy
4,636
+429
+10% +$224K ﹤0.01% 3173
2014
Q2
$1.78M Hold
4,207
﹤0.01% 3309
2014
Q1
$2.31M Buy
4,207
+391
+10% +$228K ﹤0.01% 3159
2013
Q4
$2.13M Buy
3,816
+164
+4% +$97.9K ﹤0.01% 3163
2013
Q3
$2.3M Hold
3,652
﹤0.01% 3084
2013
Q2
$1.74M Buy
+3,652
New +$1.81M ﹤0.01% 3117

Other funds holding ALT

Vanguard Group's ALT Position: Q4 2025 in Review

Vanguard Group increased its Altimmune (ALT) stake by 49% in Q4 2025, buying an estimated $13.6M and bringing the position to 9,491,159 shares worth $34.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2369.

Vanguard Group first reported a position in ALT in Q2 2013 and has held it in 50 quarters since. The position peaked at $41.7M in Q4 2022. 181 funds tracked by Wall St. Rank hold ALT as of Q4 2025.

  • Vanguard Group held 9,491,159 shares of Altimmune worth $34.3M as of Q4 2025.
  • Vanguard Group bought 3,117,521 Altimmune shares in Q4 2025, an estimated $13.6M.
  • Altimmune made up ﹤0.01% of Vanguard Group's portfolio in Q4 2025, its #2369 holding.
  • Vanguard Group first reported a position in Altimmune in Q2 2013 and has held it in 50 quarters since.
  • Vanguard Group's Altimmune position peaked at $41.7M in Q4 2022.
  • 181 funds tracked by Wall St. Rank held Altimmune as of Q4 2025.

Based on Vanguard Group's 13F filing for Q4 2025, filed 29 Jan 2026.